前列地尔注射液联合奥拉西坦注射液对血管性痴呆患者的临床效果  

Clinical effect of Alprostadil Injection combined with Oxiracetam Injection for the patients with vascular dementia

作　　者：向绍通[1] 徐书雯[1] 杨帆[1] 肖豪[1] 

机构地区：[1]广东省人民医院神经内科广东省医学科学院广东省老年医学研究所广东省神经科学研究所,广东广州510080

出　　处：《中国医药导报》2017年第8期139-142,共4页China Medical Herald

基　　金：广东省省级科技计划项目(2013B021800160)

摘　　要：目的探讨前列地尔注射液联合奥拉西坦注射液对血管性痴呆患者的临床效果。方法选取2013年6月~2016年5月在广东省人民医院神经内科治疗的75例血管性痴呆患者,随机分为前列地尔组、奥拉西坦组、联合组,每组25例。前列地尔组给予前列地尔注射液,奥拉西坦组给予奥拉西坦注射液,联合组给予前列地尔注射液联合奥拉西坦注射液治疗,连续治疗2周。分析三组患者的治疗效果、简易精神状态量表(MMSE)评分、日常生活能力量表(ADL)评分。结果联合组总有效率明显高于前列地尔组、奥拉西坦组,差异有统计学意义(P<0.05)。三组治疗前MMSE评分及ADL评分比较差异均无统计学意义(P>0.05)。三组治疗后MMSE评分及ADL评分均较治疗前显著上升(P<0.05)。治疗后,三组MMSE评分及ADL评分比较,差异均有统计学意义(P<0.05),其中联合组MMSE评分及ADL评分均明显高于前列地尔组和奥拉西坦组,差异均有统计学意义(P<0.05)。结论前列地尔注射液联合奥拉西坦注射液治疗血管性痴呆患者的临床效果较单独用药效果明显。Objective To investigate the clinical effect of Alprostadil Injection combined with Oxiracetam Injection for the patients with vascular dementia. Methods Seventy-five patients with vascular dementia treated in Department of Neurology, Guangdong General Hospital from June 2013 to May 2016 were selected and randomly divided into Alprostadil group, Oxiracetam group, combined group, with 25 cases in each group. Alprostadil group was given Alprostadil Injection,Oxiracetam group was given Oxiracetam Injection, combined group was given Alprostadil Injection combined with Oxiracetam Injection, continuous treatment for 2 weeks. The curative effect, mini-mental state examination（MMSE） score, activity of daily living（ADL） score of the three groups were analyzed. Results The total effective rate of combined group was higher than that of Alprostadil group, Oxiracetam group, the differences were statistically significant（P 〈 0.05）. There were no statistically significant differences of MMSE score and ADL score among the three groups before treatment（P 〉 0.05）. The MMSE score and ADL score in the three groups after treatment were all significantly higher than those before treatment（P 〈 0.05）. There were statistically significant differences of MMSE score and ADL score among the three groups after treatment（P 〈 0.05）, among which, the MMSE score and ADL score in the combined group were higher than those of Alprostadil group and Oxiracetam group, the differences were statistically significant（P 〈 0.05）. Conclusion The clinical effect of Alprostadil Injection combined with Oxiracetam Injection in the treatment of patients with vascular dementia is more obvious than single use.

关 键 词：前列地尔注射液 奥拉西坦注射液 血管性痴呆 临床疗效 

分 类 号：R749.13[医药卫生—神经病学与精神病学]